White Pine Capital LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) during the 3rd quarter, Holdings Channel.com reports. The firm purchased 376 shares of the company’s stock, valued at approximately $435,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Coastal Bridge Advisors LLC purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at approximately $2,959,000. Birinyi Associates Inc. lifted its position in Eli Lilly and Company by 32.6% during the 3rd quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock worth $1,689,000 after acquiring an additional 359 shares during the period. Bernicke Wealth Management Ltd. acquired a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $5,001,000. Mosaic Family Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 70.6% in the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock valued at $4,144,000 after purchasing an additional 1,430 shares during the last quarter. Finally, Trillium Asset Management LLC grew its stake in shares of Eli Lilly and Company by 1,302.8% in the 3rd quarter. Trillium Asset Management LLC now owns 5,036 shares of the company’s stock valued at $5,831,000 after purchasing an additional 4,677 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.
Latest Eli Lilly and Company News
Investors following LLY have been watching these news items:
- Positive Sentiment: Lilly agreed to acquire Calytrix Bio for up to $1.5 billion, adding experimental treatments for rare blood cancers—essential thrombocythemia and myelofibrosis—and broadening its portfolio beyond obesity drugs. The medicines are still in development, so their commercial potential is not yet established. Read article
- Positive Sentiment: New ObesityWeek data covered Zepbound, Foundayo, EloraTZP, and retatrutide, with reported efficacy signals across weight loss and related conditions. The findings may support Lilly’s pipeline and future growth prospects. Read article
- Positive Sentiment: Barclays raised its price target from $1,400 to $1,550 and maintained an “overweight” rating, signaling continued analyst confidence. Read article
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on LLY. Weiss Ratings raised Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a report on Friday. Argus increased their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a report on Friday, October 30th. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Royal Bank Of Canada lifted their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a research report on Friday, October 30th. Finally, Berenberg Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price objective on the stock in a research note on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,422.00.
Get Our Latest Analysis on Eli Lilly and Company
Eli Lilly and Company Trading Down 0.9%
NYSE LLY opened at $1,431.12 on Tuesday. The stock has a market capitalization of $1.35 trillion, a P/E ratio of 46.45, a P/E/G ratio of 1.71 and a beta of 0.40. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,475.25. The firm has a 50-day moving average price of $1,247.93 and a 200 day moving average price of $1,112.33. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter last year, the firm earned $7.02 earnings per share. The firm’s revenue was up 38.6% compared to the same quarter last year. Equities research analysts expect that Eli Lilly and Company will post 35.70 EPS for the current year.
Eli Lilly and Company Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is 22.46%.
Insider Activity
In other news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This trade represents a 54.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Read More
- Five stocks we like better than Eli Lilly and Company
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
